GE MEDICAL SYSTEMS

GE HealthCare's FDA-approved Flyrcado™ (flurpiridaz F 18) PET radiotracer offers higher diagnostic efficacy for coronary artery disease (CAD) than SPECT MPI, with a longer half-life enabling exercise stress testing and potential expansion of PET MPI access.

FDA approves Flyrcado (flurpiridaz F 18) for coronary artery disease detection, offering higher diagnostic efficacy than SPECT MPI, with a longer half-life enabling wider distribution and combined stress testing.

Tampa General Hospital (TGH) Cancer Institute, approaching its 3-year anniversary, has achieved significant progress through innovative solutions, including a 3-year COC accreditation, Newsweek's top cancer hospital recognition, and the TGH-USF Health Precision Medicine Biorepository. The institute has recruited 22 physicians and 20 advanced practice providers, and integrated CareComm for improved patient care, reducing inefficiencies by $40 million. TGH has also expanded its radiation oncology program with new technologies like CyberKnife and TrueBeam, aiming for NCI designation within the decade.

The U.S. general anesthesia drugs market is projected to grow from USD 1.98 Billion in 2024 to USD 2.56 Billion by 2033, driven by increasing surgical procedures, technological advancements, and regulatory updates. Key segments include propofol, intravenous drugs, knee and hip replacements, and hospitals, with ambulatory surgical centers expected to grow fastest. Major players include GE Healthcare, Pfizer, and Hospira Inc.

Urology Week 2024 highlights innovations from UroMems, Axonics, Procept Biorobotics, Medtronic, Asensus Surgical, Olympus, GE HealthCare, Affluent Medical, Biobot Surgical, and Avation Medical, focusing on advancements in urology treatments and technologies.

The global nuclear medicine market was valued at US$ 5.2 Bn in 2022 and is projected to reach US$ 11.4 Bn by 2031, driven by the increasing prevalence of chronic diseases and the growing availability of radiopharmaceuticals. Nuclear medicine, using radioactive materials for diagnosis and treatment, offers early detection and personalized treatment plans, crucial for conditions like cancer and heart disease. Technological advancements and rising investments in healthcare infrastructure are further fueling market growth.

GE HealthCare launches enhanced Venue Sprint point-of-care ultrasound system, combining Venue software and AI-enabled tools for maximum portability and uncompromised image quality, with wireless probe capability via Vscan Air. The tablet-form system supports care in critical care, emergency medicine, and medical transport, offering performance consistent with other Venue systems and optional clinical tools for varying user experience levels.

The global cell expansion market is projected to grow at a CAGR of 12.1% from 2024 to 2034, reaching $40.1 billion by 2034. AI and ML are revolutionizing the process, while decentralized healthcare drives portable technologies. Key players include Thermo Fisher Scientific, Miltenyi Biotec, and Merck KGaA. Stem cells and bioreactors dominate the market, with biotechnology and pharmaceutical companies leading in end-user segments. North America and Europe are major regions, with Asia Pacific witnessing rapid growth.

The Global Precision Medicine Market report covers industrial and commercial aspects, market driving forces, key players' strategies, and regional landscape. It includes detailed vendor profiles, market trends, share analysis, and forecasts from 2024 to 2032.

The global personalized medicine market is projected to grow from USD 530.11 billion in 2023 to USD 1,176.66 billion by 2033, driven by demand for novel drug discovery, collaborations, regulatory support, digital health innovations, and rising prevalence of chronic diseases. Key players include 23andMe, Inc., Abbott Laboratories, and Illumina, Inc., among others.